Shares of pharmaceutical giant Merck (NYSE: MRK) rose 3% before the market hours on Tuesday after the company reported second-quarter results that were far ahead of analysts’ expectations.
Boosted by the strength of its cancer drugs, worldwide sales increased 12% to 11.8 billion, which surpassed the average analysts’ expectation of $10.96 billion.
Sales of key oncology drug Keytruda jumped 58% to $2.63 billion, lifting the overall pharmaceutical sales up 13%.
International pharmaceutical sales represented 55% of total sales in the quarter. Performance in international markets was led by China, which had pharmaceutical sales of $745 million representing growth of 41%.
Earnings, excluding one-time items, grew 23% to $1.30 per share, 14 cents higher than the street view.
READ: Apple needs to clear many hurdles to push stock higher post Q3 earnings
Outlook
Merck raised its full-year 2019 revenue range to be between $45.2 billion and $46.2 billion. Meanwhile, it reduced its guidance for GAAP EPS range to between $3.78 and $3.88, to take into account charges related to the acquisition of Peloton.
Excluding one-time items, earnings for this period is expected between $4.84 and $4.94.
The stock has gained 27% in the trailing 52 weeks and 9% since the beginning of this year.
Most Popular
IPO Alert: Here’s what to look for when CaliberCos goes public
The massive slowdown in the IPO market continued in the second half as the challenges posed by high inflation and interest rate hikes weighed on investor confidence. Meanwhile, there is
CarMax (KMX) Stock: Does the current dip offer a buying opportunity?
The automotive sector is one of the worst affected by the combination of high inflation and rising interest rates. Consumers have become more cautious and are prioritizing their purchases with
Ultimax Digital gears up for $10mln IPO. Here’s all you need to know
The IPO market has witnessed muted activity this year, and things don’t seem to have improved in the second half. The upcoming public listing of video game technology firm Ultimax
